SK Capital has rejigged the senior teams at opiate API maker Noramco and raw material supplier Tasmanian Alkaloids just weeks after buying the firms from Johnson & Johnson (J&J).
The US private investment announced the changes today, explaining that Matthew Martin, previously the General Manager of both businesses, has been appointed as Noramco CEO.
SK Capital also hired Chris Close as CFO for both organisations and appointed Charlie Enzinger as vice president of integrated supply chain operations at Noramco
The investment firm said: The expanded team will be tasked with driving the operational improvements and customer-focused initiatives that are expected to be captured as an independent, carved-out org…
Read the full article at: http://www.in-pharmatechnologist.com/Ingredients/US-investor-buys-J-J-s-opiate-API-business-and-announces-restructuring